Bladder cancer (C67)

The following material has been sourced from the Australian Institute of Health and Welfare

Table B4(a): Incidence and mortality of bladder cancer
  Incidence - Males Incidence - Females Incidence - Persons Mortality - Males Mortality - Females Mortality - Persons
2011 incidence/2012 mortality(b)  
Number 1,806 598 2,404 707 331 1,038
Crude rate 16.2 5.3 10.8 6.3 2.9 4.6
ASR 16.2 4.3 9.6 6.3 2.1 3.9
Risk to age 75 1 in 115 1 in 410 1 in 180 1 in 386 1 in 1,120 1 in 578
Risk to age 85 1 in 43 1 in 166 1 in 71 1 in 125 1 in 347 1 in 191
Mean age 74.4 76.1 74.8 77.9 80.3 78.6
Estimated number for 2014, 2015 and 2016(c)  
2014 2,060 675 2,730 780 335 1,115
2015 2,110 690 2,800 800 340 1,140
2016 2,170 705 2,880 815 350 1,165

Figure B4(a): Incidence and mortality ASRs(b,c) of bladder cancer, 1982-2016

Line chart showing rate (per 100,000 people) of incidence and mortality of cancer of the bladder in males and females from 1982 to 2012, with estimates to 2016.

Figure B4(b): Incidence (2011) and mortality (2012) rates of bladder cancer, by age group

Line chart showing rate (per 100,000 people) of incidence (2011) and mortality (2012) of cancer of the bladder in males and females by age group. Age groups shown are: 0-4, 10-14, 20-24, 30-34, 40-44, 50-54, 60-64, 70-74 and 80-84.
  1. Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2).
  2. The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F, Cancer in Australia: an overview 2014). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population.
  3. The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 2002–2012 mortality data (see Appendix G, Cancer in Australia: an overview 2014) They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. The estimates for males and females may not add to estimates for persons due to rounding.

Sources: AIHW ACD 2011; AIHW NMD.

Table B4(b): Survival and prevalence of bladder cancer
  Males Females Persons
Prevalence as at the end of 2009(a)  
1-year prevalence 1,498 468 1,966
5-year prevalence 5,241 1,498 6,739
Relative survival in 2007-2011(b)  
1-year relative survival at diagnosis (%) 78.8 68.9 76.4
95% confidence interval 77.8-79.8 66.9-70.8 75.5-77.3
5-year relative survival at diagnosis (%) 55.2 46.8 53.1
95% confidence interval 53.8-56.5 44.5-49.0 51.9-54.3
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 66.9 66.6 66.8
95% confidence interval 64.9-68.8 63.1-70.1 65.1-68.5
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 84.0 86.7 84.7
95% confidence interval 82.1-86.0 83.6-89.9 83.0-86.3

Figure B4(c): Relative survival at diagnosis and 5-year conditional survival from bladder cancer, Australia, 2007–2011

Line chart showing rate of relative survival of bladder cancer from 2007 to 2011 by years after diagnosis. Survival rates are grouped by relative survival at diagnosis and 5-year conditional relative survival. Survival rates drop steadily over 20 years for relative survival at diagnosis; while 5-year conditional relative survival rates slowly increase over a period of 15 years.
  1. Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases.
  2. Relative survival was calculated with the period method, using the period 2007–2011 (Brenner & Gefeller 1996). Note that this period does not contain incidence data for 2010–2011 for NSW or the ACT (see Appendix F, Cancer in Australia: an overview 2014)

Source: AIHW ACD 2011.